色婷婷综合成人av_99久久精品国产毛片_成人一区二区在线_国产91丝袜在线播放_久久人人爽人人爽人人片av免费_欧美伊人

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Stem Cell Therapeutic
Stem Cell Therapeutic
Stem Cell Therapeutic Stem Cell Therapeutic

加拿大Stem Cell Therapeutic
加拿大干細胞治療公司

Stem Cell Therapeutics Corp. is a Canadian biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. The company’s programs aim to repair neurological function lost due to disease or injury.

Stem Cell Therapeutics Corp. is a biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system (“CNS”) disorders. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident autologous stem cells. The Company's programs aim to repair neurological functions lost due to disease or injury. SCT’s stem cell regenerative therapeutic approach was founded on the work of Dr. Samuel Weiss, Director of the Hotchkiss Brain Institute at the University of Calgary, who was awarded the Gairdner Award in April 2008 for this work on neural stem cells. SCT’s lead product, NTx?-265, targets the treatment of stroke by repurposing approved and clinically well defined drugs. The Company's extensive patent portfolio supports the potential expansion into future clinical programs in numerous other neurological diseases such as traumatic brain injury and multiple sclerosis.

SCT’s primary program, NTx?-265, is a therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin (“hCG”) and Erythropoietin (“EPO”), targeting the treatment of stroke. The twin objectives of the regimen are to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the stroke, and importantly, to direct motor, visual and cognitive recovery after acute ischemic stroke. Animal studies have shown a significant recovery in motor function after receiving the NTx?-265 regimen 24-48 hours post stroke. Encouraging final clinical results from SCT’s completed BETAS (Beta-hCG + Erythropoietin in Acute Stroke) Phase IIa stroke trial were presented at the International Stroke Conference in February 2009, showing clinically relevant recovery in 12 of 12 patients who received the complete regimen. In May of 2008, SCT began recruiting patients for its multi-centre, double-blind, placebo-controlled REGENESIS (a Phase II prospective, randomized, double-blind, placebo controlled study of NTx?-265: hCG and epoetin alfa in acute ischemic stroke patients) Phase IIb stroke study for NTx?-265 with primary endpoints of safety and efficacy.

Due to an unrelated German clinical study, the REGENESIS Phase IIb clinical trial was officially placed on clinical hold in September 2008 at the request of Health Canada and the U.S. Food and Drug Administration (“FDA”). The clinical hold was formally lifted by FDA on May 14, 2009. Health Canada approved the modified REGENESIS Phase IIb stroke trial on July 20, 2009and the Drug Controller General of India (“DCGI”) followed shortly thereafter on July 21, 2009 issuing the Company a No Objection Letter (“NOL”) for the same protocol. This trial is co-Led by two principal investigators: Dr. Steven C. Cramer from the University of California, Irvine and Dr. Michael D. Hill of Foothills Hospital at the University of Calgary. The recruitment target for this study is to enroll 128 patients. The Indian, U.S., and Canadian protocols share similar design, as well as safety and efficacy endpoints.

On August 11, 2009, the Company announced the enrollment of its first patient in the dose response designed modified REGENESIS Phase IIb stroke trial. It is expected that the Company will complete recruiting by the end of Q1 2010 in the modified REGENESIS phase IIb stroke trial using NTx?-265. A top-line read of the data is anticipated to be available.
 

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 91精品国产91久久久久久最新 | 亚洲免费视频一区 | 欧美在线免费 | 国产美女精品人人做人人爽 | 亚洲 成人 av| 久久这里只有精品8 | 久久久成人精品 | 精品第一页 | 精品久久99 | 日韩欧美视频 | 激情一区 | 深夜在线| 亚洲伊人成人 | 久久不卡| 成人动慢 | 亚洲精品一区二区网址 | 日韩和的一区二在线 | 亚洲男人的天堂视频 | 国产 欧美 日产久久 | 美女搞黄网站 | 午夜电影网 | 亚洲国产美女视频 | 欧美成人a∨高清免费观看 亚洲国产精品尤物yw在线观看 | 国产色 | 中国一极毛片 | 毛片黄片免费观看 | 亚洲一区 日韩精品 中文字幕 | av手机在线电影 | 欧美怡红院视频一区二区三区 | 精品国产乱码久久久久久丨区2区 | 中文成人在线 | 欧美日韩一区二区三区不卡视频 | 国产美女一区 | 成人在线免费 | 热99久久 | 欧美日韩国产在线播放 | 欧美午夜影院 | 日韩美女在线 | 国产精品一区av | 久久综合另类激情人妖 | 91麻豆精品国产91久久久更新资源速度超快 |